Table 3.
The distribution of clinical status at day 28 in patients included in the ESSENTIAL trial.
| Value | Clinical status definition | Overall population |
High sTREM-1 |
||
|---|---|---|---|---|---|
| Placebo |
Nangibotide |
Placebo |
Nangibotide |
||
| n (%) | n (%) | n (%) | n (%) | ||
| 1 | Not hospitalized, no limitations of activities | 16 (16.0%) | 20 (16.8%) | 5 (9.1%) | 1 (1.9%) |
| 2 | Not hospitalized, limitations of activities | 14 (14.0%) | 29 (24.4%) | 5 (9.1%) | 10 (18.5%) |
| 3 | Hospitalized, not requiring supplemental oxygen | 9 (9.0%) | 15 (12.6%) | 5 (9.1%) | 7 (13.0%) |
| 4 | Hospitalized, requiring supplemental oxygen | 13 (13.0%) | 13 (10.9%) | 3 (5.5%) | 8 (14.8%) |
| 5 | Hospitalized, on non-invasive ventilation or high flow oxygen devices | 1 (1.0%) | 0 (0.0%) | 1 (1.8%) | 0 (0.0%) |
| 6 | Hospitalized, on invasive mechanical ventilation or ECMO | 22 (22.0%) | 25 (21.0%) | 16 (29.1%) | 17 (31.5%) |
| 7 | Death | 25 (25.0%) | 17 (14.3%) | 20 (36.4%) | 11 (20.4%) |
The number (%) of patients in each of the seven categories is described for patients that received placebo and nangibotide in the overall population and in the subgroup of patients with high sTREM-1 defined by a sTREM-1 above the median value (239 pg/ml) at baseline.